article · Current Medical Research and Opinion
Beta-blockers form a diverse class of drugs with distinct pharmacological profiles. Individual medications vary in their receptor selectivity, partial agonist activity, vasodilatory properties, and lipophilicity, which affects their entry into the central nervous system. Cardioselective beta-blockers, which target beta-1 receptors, lessen the risk of adverse side effects caused by blocking beta-2 receptors outside the heart muscle, such as cold extremities, erectile dysfunction, and worsened respiratory conditions like asthma or chronic obstructive pulmonary disease. Recent European Society of Hypertension guidelines include beta-blockers among the five major drug classes recommended for antihypertensive therapy. Combining a beta-blocker with a complementary drug can counteract the negative effects of triggered sympathetic overactivity, supporting better blood pressure reduction and overall clinical outcomes.
High blood pressure is a widespread health challenge, and choosing the right medication is vital for patient safety and comfort. Because beta-blockers are not identical, understanding their distinct pharmacological traits allows healthcare providers to avoid distressing side effects and formulate smarter combination therapies that control blood pressure more effectively.
The insights inform clinical prescribing guidelines and the rational design of combination antihypertensive therapies. The intended end users are clinicians, medical researchers, and pharmaceutical developers looking to optimise fixed-dose combination treatments. Because these observations relate to established, guideline-recommended pharmaceutical classes, the concepts are applicable directly to current clinical practice and drug formulation strategies.
AI-generated from the published abstract. Always read the original work before citing.
β-blockers are a heterogeneous class, with individual agents distinguished by selectivity for β<sub>1</sub>- vs. β<sub>2</sub>- and α-adrenoceptors, presence or absence of partial agonist activity at one of more β-receptor subtype, presence or absence of additional vasodilatory properties, and lipophilicity, which determines the ease of entry the drug into the central nervous system. Cardioselectivity (β<sub>1</sub>-adrenoceptor selectivity) helps to reduce the potential for adverse effects mediated by blockade of β<sub>2</sub>-adrenoceptors outside the myocardium, such as cold extremities, erectile dysfunction, or exacerbation of asthma or chronic obstructive pulmonary disease. According to recently updated guidelines from the European Society of Hypertension, β-blockers are included within the five major drug classes recommended as the basis of antihypertensive treatment strategies. Adding a β-blocker to another agent with a complementary mechanism may provide a rational antihypertensive combination that minimizes the adverse impact of induced sympathetic overactivity for optimal blood pressure-lowering efficacy and clinical outcomes benefit.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/03007995.2024.2318058
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
